


ETCTN Trials by Disease/ Treatment Area: Head and Neck/Thyroid Cancer



NOTE: \* No ClinicalTrials.gov webpage is available currently (typically for approved LOIs or protocols in review).

## ETCTN Head/Neck and Thyroid Cancer Trials (Open as of 3/10/2025)

<b>Protocol Number</b>	<b>Phase</b>	<b>Protocol Title</b>
<b>10492</b>	I/Ib	Phase I/Ib Study of AKT Inhibitor Ipatasertib with Chemoradiation for Locally Advanced Head and Neck Cancer
<b>10496</b>	II	A Phase II Trial of Ipatasertib in Combination with Pembrolizumab for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
<b>10553</b>	II	A Phase II Clinical and Biomarker Study of Darolutamide in Combination with Androgen Deprivation Therapy (ADT) for Hormone-Therapy Naïve Recurrent and/or Metastatic Androgen Receptor (AR) Positive Salivary Gland Cancer Patients
<b>10706</b>	I/II	A Phase 2 Window of Opportunity Trial of Neoadjuvant Agonistic Anti-CD40 Antibody CDX-1140 and Cemiplimab in AJCC Stage III-IV Head and Neck Cancer Patients Prior to Surgery